FDA approves our application for atrial ablation clinical trial

Published by Natalia Trayanova on

FDA just approved our 160-patient randomized clinical trial to demonstrate the utility of computer simulations driving atrial ablation procedure in patients with persistent atrial fibrillation and fibrosis. The approach is termed OPTIMA (OPtimal Target Identification via Modeling of Arrhythmogenesis). The PIs are Drs. Trayanova, Calkins, and Spraag — clinicians and engineers working together! Hoping to make computer simulations part of clinical care!